Loading…
Purecraft LLC was cited for selling unapproved CBD products with claims to mitigate, prevent, treat, diagnose, or cure COVID-19, violating section 505(a) of the Federal Food, Drug, and Cosmetic Act by marketing unapproved new drugs. The products were also found to be misbranded drugs under section 502 of the FD&C Act, with marketing conducted through the company's website and social media platforms (Facebook and Instagram). This enforcement action occurred during the COVID-19 public health emergency, when the FDA was taking urgent measures to protect consumers from unauthorized products making disease claims without FDA approval.